@prefix dc1: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix bl: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: a np:Nanopublication;
np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo .
}
sub:assertion {
bl:category bl:Disease .
sub:association a rdf:Statement;
rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
rdfs:label "rexulti is indicated for adjunctive treatment of major depressive disorder mdd see clinical studies 14 1 treatment of schizophrenia see clinical studies 14 2 rexulti is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder mdd 1 14 1 treatment of schizophrenia 1 14 2";
bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
bl:provided_by ;
bl:relation schema:TreatmentIndication .
bl:category bl:Drug .
}
sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "Uu+l+iXcqzchYuvMiKFY12sV3nJ7wWPCX9vVrsP7+xc67SKix6x3lp7l7bkB58khWNATxErXqg5yDMkE07mrUqMrd5v7cjvJG6Js4JbzzApk37Yzn1z6daudrRxeFDmDzTnBgMqyZUIE0mrDAabm48KdIGhBn47XOEXYfc3fBkQ=";
npx:hasSignatureTarget this: .
this: dc1:created "2021-06-12T12:58:17.587+02:00"^^xsd:dateTime;
dc1:creator orcid:0000-0002-1468-3557;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}